I am a
Home I AM A Search Login

Papers of the Week


Papers: 29 Feb 2020 - 6 Mar 2020


Pharmacology/Drug Development

PAIN TYPE:
Itch


2020


J Asthma Allergy


13

Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis.

Authors

Loh TY, Hsiao JL, Shi VY
J Asthma Allergy. 2020; 13:109-114.
PMID: 32104006.

Abstract

Atopic dermatitis (AD) is a chronic, relapsing skin condition with a wide disease spectrum. Moderate-to-severe cases often need systemic treatment. Conventional immunosuppressants have extensive side effect profiles and require close monitoring. In recent decades, there has been increasing interest in developing targeted systemic immunomodulators for AD, as they have been shown to have efficacy for AD as well as favorable safety profiles. Herein, we review the recent data on lebrikizumab, an interleukin (IL)-13 inhibitor, and its potential role in the treatment of AD.